alexa Allergen Immunotherapy High Impact Factor Journals|OMICS International|Journal Of Allergy And Therapy

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Allergen Immunotherapy High Impact Factor Journals

Allergen immunotherapy, also called desensitization aims at patients suffering from allergies. It is a long-term treatment which decreases allergic symptoms by increasing tolerance to the specific allergen and involves the repeated administration of allergenic extracts to the patients either subcutaneously or sublingually for the treatment of allergic respiratory diseases. Allergen immunotherapy improves the existing symptoms of allergic rhinitis, conjunctivitis, asthma or stinging insect allergy. Allergen immunotherapy is the cost-effective adjunctive treatment in modifying the existing disease state. This immunotherapy is associated with a shift from Th2 to Th1 immune responses, and the production of T regulatory cells that reduce the immune response to relevant allergens. Allergen immunotherapy is regularly recommended for treatment of allergic rhinitis due to pollen or dust mite allergy and for asthma if the symptoms are severe and if the patient wants to avoid medication and side effects. High-impact journals are those considered to be highly influential in their respective fields.It is first devised by Eugene Garfield, the founder of the Institute for Scientific Information. The impact factor of a journal is evaluated by dividing the number of current year citations to the source items published in that journal during the previous two years.
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger

Last date updated on July, 2014